Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)
Status:
Withdrawn
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of
Rapastinel, compared to 10 mg of Vortixetine and placebo in participants with major
depressive disorder (MDD).